Literature DB >> 328129

VM 26 and VP 16-213: a comparative analysis.

M Rozencweig, D D Von Hoff, J E Henney, F M Muggia.   

Abstract

VM 26 and VP 16-213 are epipodophyllotoxin analogs. This paper presents a comparative analysis of their experimental and clinical features but fails to disclose any significant difference between these drugs. Similar studies with other classes of compounds might help to define some rationale for the development of analogous cytotoxic agents.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 328129     DOI： 10.1002/1097-0142(197707)40:1<334::aid-cncr2820400147>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  30 in total

1.  Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.

Authors:  D Fulton; R Urtasun; P Forsyth
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

2.  Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation.

Authors:  P B Jensen; H Roed; T Skovsgaard; E Friche; L Vindeløv; H H Hansen; M Spang-Thomsen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma.

Authors:  P Canal; R Bugat; C Michel; H Roche; G Soula; P F Combes
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents.

Authors:  R T Dorr; D S Alberts
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

5.  Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide.

Authors:  D J Stewart; D Grewaal; M D Redmond; N Z Mikhael; V A Montpetit; R Goel; R M Green
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  A phase I trial of continuous infusion VP16-213 (etoposide).

Authors:  J Aisner; D A Van Echo; M Whitacre; P H Wiernik
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Pharmacokinetics of VP16-213 given by different administration methods.

Authors:  M D'Incalci; P Farina; C Sessa; C Mangioni; V Conter; G Masera; M Rocchetti; M B Pisoni; E Piazza; M Beer; F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice.

Authors:  T Colombo; M Broggini; L Torti; E Erba; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 9.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms.

Authors:  J Mortimer; R M Bukowski; J Montie; J S Hewlett; R B Livingston
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.